


Responsible Antibiotic Manufacturing Platform (RAMP) Project

April 2021- March 2024

Global Programme Water (GPW), Global Programme Health (GPH)

with support from Swiss Cooperation Office India



Multi stakeholder platform partnering with GSK, Centrient, Novartis/Sandoz, Stockholm International Water Institute (SIWI), Shawview consulting & AMR Industry Alliance

Why India ?

- India is the largest producer of antibiotics (supply to global market > 40%).
- Industry is diverse (small, medium and large enterprises); manufacturing & formulation of diverse antibiotics and therapeutic drugs.
- Pharma production units (bulk drugs only) classified as Grossly Polluting Industry (GPI) require effluent treatment plants (ETP) with zero discharge
- Reports of extremely high concentrations of antibiotics near manufacturing plants in Pharma hubs (water samples found to be drug resistant to over 30 commonly used antibiotics).
- India launched a “National Programme on Antimicrobial Resistance
- It is implementing a national AMR strategy; several states developing state AMR action plans.

RAMP project seeks to develop public private partnerships to reduce the spread of antibiotic resistance (AMR) caused by environmental pollution from antibiotic manufacturing and enabling sustainable antibiotics production.

Objectives

- showcase the state and feasibility of improvements in manufacturing and procurements through pilots
- upscale the application of available solutions and address gaps by promoting innovation
- promote enabling ecosystem through stakeholders engagement and advocacy for supportive policy, science and technologies